



BACH


Biomarkers in Acute Heart Failure (AHF)

BACKGROUND: Natriuretic peptides have well established prognostic value in AHF. Mid-regional pro-Adrenomedullin (proADM) is a marker of endothelial function & previous studies suggest it is a strong prognosticator in AHF patients.

PURPOSE: To test for superiority of proADM vs BNP to predict 90 day mortality.

DESIGN: Prospective, 15 center international trial of 1,641 pts presenting to the ED with SOB.

Prognostic Accuracy (%) for proADM vs BNP vs NTproBNP



Primary Endpoint Results:

Prognostic Accuracy

MR-proADM 73.5% vs BNP 60.8% (p<0.001)

vs NT-proBNP 63.6% (p<0.001)

Conclusion:

proADM is superior to BNP, regardless of troponin levels, for predicting 90 day mortality in pts with SOB & HF.